Explore
FTO (Freedom to Operate) in the Pharmaceutical Industry
Hirotaka Nonaka
2018
0 Ungluers have
Faved this Work
Login to Fave
FTO licensing in the pharmaceutical industry deserves special consideration because of the large economic scale of the market, expensive cost of R&D, extremely low success rate, and easy duplication of the drug. Taking these unique aspects into consideration, the author first explaines how to perform a good FTO search and conclude an appropriate FTO licensing agreement, and then points out two issues; (i) the issue of FTO licensing and EU competition, especially the unreasonable application of the Guideline, and (ii) the issue of FTO licensing and differentiating between a bio venture company and a pharmaceutical company. Solutions for these issues are proposed.The author is HIROTAKA NONAKA; an attorney-at-law and patent attorney in Tokyo, Japan, handling particularly IP-related disputes and consulting.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 51 times via unglue.it ebook links.
- 51 - pdf (CC BY-NC-ND) at Unglue.it.
Keywords
- Antitrust law
- EU competition law
- Freedom to Operate
- FTO
- FTO-licensing market
- Law
- License
- patent
- pharmaceutical
- Pharmaceutical industry
Links
DOI: 10.5771/9783845294018Editions